23Andme Holding Co
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic a… Read more
23Andme Holding Co (ME) - Net Assets
Latest net assets as of December 2024: $62.72 Million USD
Based on the latest financial reports, 23Andme Holding Co (ME) has net assets worth $62.72 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($277.42 Million) and total liabilities ($214.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $62.72 Million |
| % of Total Assets | 22.61% |
| Annual Growth Rate | -9.69% |
| 5-Year Change | 40.48% |
| 10-Year Change | N/A |
| Growth Volatility | 214.23 |
23Andme Holding Co - Net Assets Trend (2019–2024)
This chart illustrates how 23Andme Holding Co's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 23Andme Holding Co (2019–2024)
The table below shows the annual net assets of 23Andme Holding Co from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-03-31 | $188.52 Million | -73.59% |
| 2023-03-31 | $713.94 Million | -22.03% |
| 2022-03-31 | $915.66 Million | +253.73% |
| 2021-03-31 | $-595.62 Million | -543.83% |
| 2020-03-31 | $134.20 Million | -57.23% |
| 2019-03-31 | $313.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 23Andme Holding Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 163033200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $49.00K | 0.03% |
| Other Components | $2.36 Billion | 1252.68% |
| Total Equity | $188.52 Million | 100.00% |
23Andme Holding Co Competitors by Market Cap
The table below lists competitors of 23Andme Holding Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JET Optoelectronics Co., Ltd.
TWO:2255
|
$9.76 Million |
|
M & A EQUITY HOLDINGS BERHAD
KLSE:7082
|
$9.77 Million |
|
Catskill Hudson Bancorp Inc
PINK:CSKL
|
$9.77 Million |
|
Interwood-Xylemporia A.T.E.N.E.
AT:XYLEK
|
$9.77 Million |
|
Ikonisys SA
PA:ALIKO
|
$9.76 Million |
|
Massimo Group Common Stock
NASDAQ:MAMO
|
$9.76 Million |
|
We Buy Cars Hlds Ltd
JSE:WBC
|
$9.76 Million |
|
Homeritz Corporation Bhd
KLSE:5160
|
$9.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 23Andme Holding Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 713,939,000 to 188,520,000, a change of -525,419,000 (-73.6%).
- Net loss of 666,704,000 reduced equity.
- Share repurchases of 3,262,000 reduced equity.
- Other comprehensive income increased equity by 620,000.
- Other factors increased equity by 143,927,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-666.70 Million | -353.65% |
| Share Repurchases | $3.26 Million | -1.73% |
| Other Comprehensive Income | $620.00K | +0.33% |
| Other Changes | $143.93 Million | +76.35% |
| Total Change | $- | -73.59% |
Book Value vs Market Value Analysis
This analysis compares 23Andme Holding Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-03-31 | $15.44 | $0.61 | x |
| 2020-03-31 | $6.60 | $0.61 | x |
| 2021-03-31 | $-29.31 | $0.61 | x |
| 2022-03-31 | $41.95 | $0.61 | x |
| 2023-03-31 | $31.62 | $0.61 | x |
| 2024-03-31 | $7.92 | $0.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 23Andme Holding Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -353.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -303.55%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 2.10x
- Recent ROE (-353.65%) is below the historical average (-115.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -58.49% | -41.63% | 0.63x | 2.22x | $-214.91 Million |
| 2020 | -215.58% | -94.71% | 0.75x | 3.02x | $-302.73 Million |
| 2021 | 0.00% | -75.17% | 0.54x | 0.00x | $-123.80 Million |
| 2022 | -23.75% | -79.99% | 0.24x | 1.26x | $-309.06 Million |
| 2023 | -43.65% | -104.06% | 0.32x | 1.32x | $-383.05 Million |
| 2024 | -353.65% | -303.55% | 0.56x | 2.10x | $-685.56 Million |
Industry Comparison
This section compares 23Andme Holding Co's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 23Andme Holding Co (ME) | $62.72 Million | -58.49% | 3.42x | $9.76 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |